Yoshiaki Furukawa

Summary

Affiliation: Centre for Addiction and Mental Health
Country: Canada

Publications

  1. ncbi request reprint Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, The Clarke Division, Toronto, Ontario, Canada
    Neurology 54:1193-5. 2000
  2. ncbi request reprint Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Mov Disord 19:1256-8. 2004
  3. ncbi request reprint Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Neurology 61:269-70. 2003
  4. ncbi request reprint Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Ann Neurol 51:637-41. 2002
  5. ncbi request reprint Brain proteasomal function in sporadic Parkinson's disease and related disorders
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Ann Neurol 51:779-82. 2002
  6. ncbi request reprint Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neurology 56:260-3. 2001
  7. ncbi request reprint Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008
  8. doi request reprint Brain serotonin transporter in human methamphetamine users
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 202:649-61. 2009
  9. doi request reprint Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans
    Isabelle Boileau
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
    Synapse 64:417-20. 2010
  10. ncbi request reprint Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Canada
    Ann Neurol 55:125-9. 2004

Collaborators

Detail Information

Publications41

  1. ncbi request reprint Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, The Clarke Division, Toronto, Ontario, Canada
    Neurology 54:1193-5. 2000
    ..Our data suggest that the DYT1 mutation is not associated with significant damage to the nigrostriatal DA system, in keeping with the absence of parkinsonism and levodopa response in this disorder...
  2. ncbi request reprint Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Mov Disord 19:1256-8. 2004
    ..Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders...
  3. ncbi request reprint Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Neurology 61:269-70. 2003
  4. ncbi request reprint Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Ann Neurol 51:637-41. 2002
    ..Our data suggest that the extent of striatal tyrosine hydroxylase protein loss may be critical in determining dopa-responsive dystonia symptomatology...
  5. ncbi request reprint Brain proteasomal function in sporadic Parkinson's disease and related disorders
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Ann Neurol 51:779-82. 2002
    ..Our brain data suggest that a systemic, global disturbance in the catalytic activity and degradation ability of the proteasome itself is unlikely to explain the cause of Parkinson's disease...
  6. ncbi request reprint Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neurology 56:260-3. 2001
    ..The data expand the clinical spectrum of TH deficiency and suggest that TH mutations may account for some patients with DRD simulating spastic paraplegia...
  7. ncbi request reprint Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008
    ....
  8. doi request reprint Brain serotonin transporter in human methamphetamine users
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 202:649-61. 2009
    ....
  9. doi request reprint Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans
    Isabelle Boileau
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
    Synapse 64:417-20. 2010
    ..Our data suggest that a low amphetamine dose is unlikely to cause sufficient DA depletion to detect increased (+)[11C]DTBZ binding and that a higher dose might be required...
  10. ncbi request reprint Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Canada
    Ann Neurol 55:125-9. 2004
    ..The supersensitive dopamine D(1) receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy...
  11. pmc D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia
    Doris E Payer
    From the Addictions Program D E P, I B, the Research Imaging Centre D E P, S J K, J T, P R, S H, A A W, I B, and the Human Brain Laboratory M G, S J K, Y F, Centre for Addiction and Mental Health, Toronto Campbell Family Mental Health Research Institute S J K, J T, P R, S H, A A W, I B, Toronto the Departments of Psychiatry D E P, S J K, J T, A A W, I B and Pharmacology S J K, University of Toronto and the Centre for Movement Disorders M G, J R A, Markham, Canada
    Neurology 86:224-30. 2016
    ..To investigate whether levodopa-induced dyskinesias (LID) are associated with D3 overexpression in levodopa-treated humans with Parkinson disease (PD)...
  12. pmc Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study
    Isabelle Boileau
    Addiction Imaging Research Group, Vivian M Rakoff PET Imaging Centre, Human Brain Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    J Neurosci 32:1353-9. 2012
    ..Pharmacological studies are needed to establish whether normalization of D3 receptor function could reduce vulnerability to relapse in stimulant abuse...
  13. doi request reprint Is brain gliosis a characteristic of chronic methamphetamine use in the human?
    Junchao Tong
    Human Brain Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Addiction Imaging Research Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Electronic address
    Neurobiol Dis 67:107-18. 2014
    ..However, a logistically more difficult quantitative histopathological study is needed to confirm whether glial changes occur or do not occur in brain of human methamphetamine (and amphetamine) users...
  14. pmc Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies
    Junchao Tong
    Human Brain Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Cereb Blood Flow Metab 31:2065-75. 2011
    ....
  15. doi request reprint Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease
    Isabelle Boileau
    Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada
    Brain 132:1366-75. 2009
    ....
  16. pmc Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation
    Junchao Tong
    Human Brain Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Addiction Imaging Research Group, Campbell Family Mental Health Research Institute, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Electronic address
    Neurobiol Dis 82:243-53. 2015
    ..Should astrogliosis protect, to some extent, the degenerating substantia nigra from damage, therapeutics aimed at normalization of astrocyte reaction in PD could be helpful. ..
  17. doi request reprint [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders
    Doris E Payer
    Addictions Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mov Disord 30:160-6. 2015
    ....
  18. pmc Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies
    Junchao Tong
    Human Brain Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    J Cereb Blood Flow Metab 33:863-71. 2013
    ..However, compared with in vitro data, the latter PET measures underestimated regional contrast by ∼2-fold. Further studies are needed to address cause of the in vivo vs. in vitro nonproportionality...
  19. pmc Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Brain 133:1779-97. 2010
    ....
  20. ncbi request reprint Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
    Paul S Fitzmaurice
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mov Disord 18:969-76. 2003
    ....
  21. ncbi request reprint Genetics and biochemistry of dopa-responsive dystonia: significance of striatal tyrosine hydroxylase protein loss
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Adv Neurol 91:401-10. 2003
    ..A clarification of the mechanism of striatal TH protein loss in GTPCH-deficient DRD may provide a new clue to the pathogenesis of this major form of DRD...
  22. pmc Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence
    Isabelle Boileau
    Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Neuropsychopharmacology 41:1179-87. 2016
    ..Further study is necessary to establish whether those users who could not maintain abstinence for the second scan might have a more severe and persistent dopamine deficiency and who could benefit from this medication. ..
  23. doi request reprint Do glutathione levels decline in aging human brain?
    Junchao Tong
    Human Brain Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8 Addiction Imaging Research Group, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Electronic address
    Free Radic Biol Med 93:110-7. 2016
    ..Since our findings, although suggestive, suffer from the generic limitations of all postmortem brain studies, we also suggest the need for "replication" investigations employing the new (1)H MRS imaging procedures in living human brain. ..
  24. ncbi request reprint [Dopa-responsive dystonia: clinical, genetic, and biochemical studies]
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Rinsho Shinkeigaku 46:19-34. 2006
    ....
  25. ncbi request reprint Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Neurochem 102:1691-702. 2007
    ..This suggests that noradrenaline signalling is much less spatially and temporally restricted in the caudomedial accumbens than in other noradrenaline-rich brain areas...
  26. pmc Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain
    Junchao Tong
    Addiction Imaging Research Group, Vivian Rakoff PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neurobiol Dis 41:458-68. 2011
    ..Further investigation will be required to establish whether this pattern, which was inversely correlated with the pattern of dopamine loss in PD, is involved to any extent in the pathophysiology of this degenerative disorder...
  27. ncbi request reprint Update on dopa-responsive dystonia: locus heterogeneity and biochemical features
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Adv Neurol 94:127-38. 2004
  28. ncbi request reprint Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Am J Psychiatry 160:896-903. 2003
    ..To establish whether dopamine D(1) receptor function might be altered in human methamphetamine users, the authors measured dopamine-stimulated adenylyl cyclase activity in the brain of chronic human users of the drug...
  29. ncbi request reprint Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada M5T 1R8
    Nucl Med Biol 32:123-8. 2005
    ..However, there has been no consistency in the selection of a "SERT-free" reference region for the estimation of free and nonspecific binding, as occipital cortex, cerebellum and white matter have all been employed...
  30. ncbi request reprint [Dopa-responsive dystonia]
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division
    Rinsho Shinkeigaku 46:769-73. 2006
    ..This TH protein reduction in the striatum (especially in the putamen) may be due to a diminished regulatory effect of BH4 on stability of TH molecules or to a dysfunction of TH protein transport from the substantia nigra to the striatum...
  31. ncbi request reprint Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency
    Yoshiaki Furukawa
    Ann Neurol 55:147-8. 2004
  32. ncbi request reprint Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum
    John W Haycock
    Department of Biochemistry and Molecular Biology, Louisiana State University Health Science Center, New Orleans 70119, USA
    J Neurochem 87:574-85. 2003
    ..This suggests that declines in DA-related function during adulthood and senescence may be explained by losses in DA per se as opposed to DAergic neuropil...
  33. doi request reprint RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells
    Hiroshi Doi
    Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, 2 1 Hirosawa Wako shi, Saitama, Japan
    J Biol Chem 283:6489-500. 2008
    ..Because TLS has a variety of functional roles, the sequestration of TLS to polyQ aggregates may play a role in diverse pathological changes in the brains of patients with polyQ diseases...
  34. ncbi request reprint VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, B C, Canada
    Synapse 49:20-8. 2003
    ..This is in keeping with a role for VMAT2 in other cellular processes (i.e., sequestration and release from the cell of potential toxic products), in addition to its importance for the quantal release of monoamines...
  35. ncbi request reprint Peptidase activities of the 20/26S proteasome and a novel protease in human brain
    Sophie Vigouroux
    Laboratoire de Biochimie Appliquée UA INRA 995, Universite Blaise Pascal, Aubiere, France
    J Neurochem 84:392-6. 2003
    ....
  36. ncbi request reprint Inherited myoclonus-dystonia: how many causative genes and clinical phenotypes?
    Yoshiaki Furukawa
    Neurology 59:1130-1. 2002
  37. pmc Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice
    Yoshiaki Furukawa
    Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA
    Proc Natl Acad Sci U S A 103:7148-53. 2006
    ..The findings provide a biochemical basis for a pathological hallmark of this disease; namely, incorrect disulfide cross-linking of the immature, misfolded mutant proteins leads to insoluble aggregates...
  38. pmc Current concepts in the diagnosis and management of Parkinson's disease
    Mark Guttman
    Department of Medicine, University of Toronto, Ont, Canada
    CMAJ 168:293-301. 2003
    ..Surgical treatment is an option for a defined patient population...
  39. pmc Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis
    Yoshiaki Furukawa
    Department of Chemistry, Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois 60208, USA
    Antioxid Redox Signal 8:847-67. 2006
    ..The authors review here a mechanism for posttranslational activation of SOD1 and discuss models for ALS in which the most immature forms of the SOD1 polypeptide exhibits propensity to form toxic aggregates...
  40. pmc Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS
    Yoshiaki Furukawa
    Department of Chemistry, Northwestern University, Evanston, IL 60208, USA
    EMBO J 23:2872-81. 2004
    ..Thus Cu-CCS mediation of correct disulfide formation in SOD1 is important for regulation of enzyme activity and for prevention of misfolding or aggregation...
  41. pmc Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria
    Han Xiang Deng
    Davee Department of Neurology and Clinical Neurosciences, Northwestern University Feinberg School of Medicine, Tarry Building, Room 13 715, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Proc Natl Acad Sci U S A 103:7142-7. 2006
    ..Importantly, rational therapy based on these observations can now be developed and tested...